Colon cancer: THIS common over-the-counter medication slashes risk of colorectal cancer recurrence in half
A groundbreaking study reveals that a daily low dose of aspirin can significantly reduce the risk of colorectal cancer recurrence by approximately 55% in patients with specific PI3K pathway mutations. The ALASCCA trial demonstrated that aspirin, when taken for three years post-surgery, offers substantial benefits for those with these genetic alterations.
A groundbreaking study reveals that a daily low dose of aspirin can significantly reduce the risk of colorectal cancer recurrence by approximately 55% in patients with specific PI3K pathway mutations. The ALASCCA trial demonstrated that aspirin, when taken for three years post-surgery, offers substantial benefits for those with these genetic alterations.
